The pharmaceutical industry is massive, worth over $1.7 trillion globally in 2024. So when an up-and-coming player emerges, it can deliver life-changing returns for investors fortunate enough to get in early. Roivant Sciences (NASDAQ: ROIV) certainly seems like a rising star. The biotech stock has more than tripled over the past year, soaring to $35 per share and a market cap of $25 billion.
Roivant is a biotech company turning a loaded pipeline into reality, and its sales could soar into the billions of dollars over the next five years. But can the stock continue to deliver multibagger returns? That won’t be as easy after its recent ascension. Here’s some math to consider when setting expectations for the stock.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images
A loaded pipeline with big things ahead
Roivant Sciences builds small, focused subsidiaries called Vants that develop drug products and technologies to treat various diseases and health conditions. Across these Vants, Roivant has amassed an impressive pipeline that management expects will have three commercial launches over the next three years. Its lead drug candidate is brepocitinib, an oral drug for treating dermatomyositis, a chronic inflammatory disease affecting the skin and muscles.
The company has only generated $8.3 million in revenue over the past 12 months, but that’s about to change in a big way. Wall Street estimates compiled by market intelligence company Fintel peg 2027 revenue at approximately $1 billion, rising to $4.5 billion in 2031. Now, those estimates assume that drug approvals go as planned, which isn’t a certainty by any means. Still, the market expects enormous growth from Roivant Sciences, which helps explain the stock’s recent rise.
Why buying now…
..
